• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Kodiak's Eylea rival hits 'major disappointment' with failure in first of 6...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Feb 23, 2022 at 09:42: PM
via Kodiak Sciences' attempt to rival Regeneron and Bayer's blockbuster drug Eylea, KSI-301, has flopped the first in a series of six phase 3 studies, casting an ominous cloud over the rest of the program.

article source
 




Top Bottom
Back
Quote